CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 216 enrolled
Drug / intervention
CRT-Ddevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02097290
NCT02097290N/ACompleted

CAPTure Information Via Automatic Threshold Evaluation

Boston Scientific Corporation·interventional·Posted Mar 27, 2014·Updated Apr 19, 2018

In Brief

A clinical study evaluating CRT-D for Heart Failure. Completed, enrolled 216 participants across 36 sites.

Detailed Summary

This study will evaluate the PaceSafe Right Ventricular Autothreshold (RVAT) and Left Ventricular Autothreshold (LVAT) features for AUTOGEN Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 27, 2014
Enrollment StartApr 1, 2014
Primary CompletionJan 1, 2016
Study CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.3 years ago

Interventions

CRT-Ddevice

For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated